Jana Marlen Ackermann to be new Head of Investor Relations at Bayer

Leverkusen, June 9, 2026 – Jana Marlen Ackermann will take over as Head of the Investor Relations department of Bayer AG effective August 1, 2026. She currently serves as Finance Head Asia for Bayer’s Crop Science Division in Singapore. In her new role, she will report to the Chairman of the Board of Management (CEO), Bill Anderson. Ackermann succeeds Dr. Jost Reinhard, who has headed the Investor Relations department since October 2023 and will assume responsibility for the Radiology Business of the Pharmaceuticals Division effective August 1. To ensure a smooth transition, Reinhard will continue to be involved in the communication for the second quarter at the beginning of August.

Jana Marlen Ackermann studied business administration and political science and earned her MBA at the Instituto de Empresa in Madrid, Spain, in 2008. Ackermann’s career at Bayer began in 2004 as a trainee and her first permanent station was at Internal Audit. She then held various positions of increasing responsibility in the areas of Strategy and Finance in Europe, Latin America and Asia. For example, she was active at Investor Relations as of 2020 and was appointed Chief Financial Officer (CFO) of Bayer in Brazil two years later. From there, she transferred to Singapore in 2024, where she served as Finance Head Asia at Crop Science.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Note:
Print-quality photos can be downloaded from our website at
www.bayer.com/media/

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contact for media inquiries:
Christian Hartel, phone +49 214 30-47686
Email: christian.hartel@bayer.com

Philipp Blank, phone +49 214 30-20499
Email: philipp.blank@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team